Andrew David Morley
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrew David Morley.
Bioorganic & Medicinal Chemistry | 2001
Peter Charles Astles; Neil Victor Harris; Andrew David Morley
Design and synthesis of a library as potential VLA-4 antagonists has been accomplished, based around a proposed pharmacophoric model. Compounds possessing submicromolar potency were identified and structure-activity relationships were seen across the library. Further derivatisation produced compounds with IC(50)s <10 nmol for inhibiting the VLA-4 mediated binding of fibronectin to RAMOS cells, providing an ideal starting point for a lead optimisation Programme.
Tetrahedron Letters | 2002
John M. Gardiner; Andrew D. Goss; Tahir Nadeem Majid; Andrew David Morley; Robin G. Pritchard; John E. Warren
A variety of novel N-alkoxy aromatic-fused imidazoles have been prepared in a simple two-step process from 2-fluoro nitroaromatics and 2-chloro-3-nitropyridine. The imidazole forming step involves tandem heterocyclisation and O-alkylation with an in situ alkylating agent, and supports prior mechanistic proposals. Additional mechanistic experiments are described. The protocol is versatile with respect to both substrate halo-nitro aromatics and to the nature of the added electrophile (halides) used in the second step, and thereby significantly extends the scope of this reaction and its applicability to diverse synthesis. This methodology can also be used to generate various types of novel N-alkoxypyrimidazoles (4-deazapurine analogues), and an X-ray structure of one such pyrimidazole is presented
Tetrahedron Letters | 2000
Andrew David Morley
Abstract Functionalisation of a series of resin bound phenolic amino acids is described, employing Irori technology to produce multidimensional libraries.
Tetrahedron Letters | 2000
Andrew David Morley
Abstract Bis-protection of phenolic amino acids can be achieved in a one-pot procedure using allyl chloroformate. Subsequent immobilisation via the free acid onto solid support then permits the carbonate protecting group to be selectively removed under mild conditions.
Tetrahedron Letters | 2003
John M. Gardiner; Andrew D. Goss; Tahir Nadeem Majid; Andrew David Morley
Abstract Synthesis of two new types of ‘head-to-head’ N , N -alkoxy bisbenzimidazoles is described. The proposed intermediate N -oxy benzimidazole from base-induced heterocyclization of N -alkylnitroanilines can be trapped with a biselectrophile (to give an N , N -linked dimer), or double heterocyclization of dimeric nitroanilines can be intercepted by electrophile trapping of both N -oxybenzimidazole termini to give C2,C2-linked dimers. These represent two regioisomeric motifs constituting new classes of benzimidazole dimers.
Archive | 1993
Garry Fenton; Andrew David Morley; Malcolm Norman Palfreyman; Andrew James Ratcliffe; Brian William Sharp; Keith Alfred James Stuttle; Sukanthini Thurairatnam; Bernard Vacher
Archive | 2002
Michael Edwards; Paul Joseph Cox; Shelley Amendola; Stéphanie Deprets; Timothy A. Gillespy; Christopher David Edlin; Andrew David Morley; Charles J. Gardner; Brian Pedgrift; Herve Bouchard; Didier Babin; Laurence Gauzy; Brun Alain Le; Tahir Nedeem Majid; John C. Reader; Lloyd J. Payne; Nawaz M. Khan; Michael Cherry
Journal of Medicinal Chemistry | 2000
Peter Charles Astles; Thomas J. Brown; Frank Halley; Caroline M. Handscombe; Neil Victor Harris; Tahir N. Majid; Clive Mccarthy; Iain M. McLay; Andrew David Morley; Barry Porter; Alan Geoffrey Roach; Carol Sargent; Christopher Smith; Roger John Aitchison Walsh
Archive | 1999
Peter Charles Astles; Neil Victor Harris; Andrew David Morley
Archive | 2000
David Edward Clark; Paul Robert Eastwood; Neil Victor Harris; Clive McCarthy; Andrew David Morley; Stephen Dennis Pickett